BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next
BridgeBio Pharma shares rose 0.5% to $76.66 Friday after announcing a $550 million convertible notes sale with a 0.75% interest rate and a $110.58 conversion price. The company expects $538.4 million in net proceeds and plans to use funds to repay 2027 notes and for general purposes. Trading volume reached about 5.9 million shares. The sale is set to close January 21.
